Shares of Clearwater Analytics Holdings, Inc. (NYSE:CWAN) rose sharply in pre-market trading.A consortium of private equity firms, led by Permira and Warburg Pincus, announced a deal to buy investment and accounting software company Clearwater Analytics on Sunday, for about $8.4 billion, including debt.Clearwater Analytics shares jumped 7.6% to $23.93 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersAutozi Internet Technology (Global) Ltd. (NASDAQ:AZI) surged ...

With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result On December 17, 2025, H.C. Wainwright raised its price target on DBV Technologies S.A. (NASDAQ:DBVT) from $35 to $40, while reiterating a “Buy” rating, The Fly reported. The firm described the Phase 3 VITESSE trial as a clear executio ...

美股市场表现 - 周三美股表现分化 道琼斯指数上涨超过150点 [1] - Toro公司股价因季度业绩超预期而大幅上涨7%至77.82美元 [1] Toro公司业绩详情 - 季度每股收益为0.91美元 超出分析师普遍预期的0.87美元 [1] - 季度销售额达10.66亿美元 超出分析师普遍预期的10.48亿美元 [1] 其他大幅上涨股票及原因 - DBV Technologies股价飙升35.5%至24.36美元 因其三期VITESSE试验顶线结果达到主要终点 [3] - Udemy股价上涨26.5%至6.79美元 因Coursera与其签署全股票合并协议 [3] - Kodiak Sciences股价上涨16.7%至28.16美元 公司宣布增发普通股的定价 [3] - Hut 8股价上涨16.3%至42.88美元 公司宣布与Anthropic和Fluidstack合作加速美国超大规模AI基础设施部署 并与Fluidstack签署为期15年价值70亿美元的租赁合同 租用其路易斯安那州River Bend数据中心园区245兆瓦的IT容量 [3] - Canopy Growth股价上涨16.2%至2.13美元 有报道称特朗普总统将签署行政命令将大麻重新归类为附表III药物 大麻相关股票普遍走高 [3] - Uniqure股价上涨15.8%至25.34美元 [3] - Sigma Lithium股价上涨15.6%至11.83美元 宜春自然资源局宣布计划取消27个采矿许可证后 锂相关股票走高 [3] - Recursion Pharmaceuticals股价上涨13.2%至4.76美元 因摩根大通将其评级从中性上调至增持 目标价从10美元上调至11美元 [3] - Two Harbors Investment股价飙升13.2%至11.21美元 公司宣布将被UWM Holdings收购 [3] - BGM Group股价上涨11.7%至5.60美元 [3] - AXT Inc股价上涨10.5%至14.36美元 [3] - Quantumscape股价上涨7.7%至11.66美元 公司宣布通过与一家新的全球前十汽车制造商客户签署联合开发协议 锁定了其2025年商业路线图 [3] - Jabil Inc股价上涨7%至227.50美元 公司公布的第一季度业绩超预期 [3] - ABM Industries股价上涨6.8%至48.87美元 因季度销售业绩乐观 [3] - Rezolve AI股价上涨6.5%至3.16美元 [3]

DBV Technologies S.A. (NASDAQ:DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.DBV Technologies stock is challenging resistance. What’s driving DBVT to record levels?Trial DataThe pivotal trial met its primary endpoint.VIASKIN Peanut demonstrated a statistically significant treatment effect, with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria after 12 mo ...

DBV Technologies盘前大涨超30%。消息上，DBV Technologies宣布了VIASKIN花生贴片在4-7岁花生过 敏儿童中的3期VITESSE试验取得了积极的初步结果，达到了其主要终点。针对4-7岁儿童的BLA提交按 计划将在2026年上半年进行。 | DBVT DBV Technologies | | | | --- | --- | --- | | 17 980 L -0.310 -1.69% | | 收盘价 12/16 16:00 美东 | | 23.400↑ 5.420 +30.14% | | 盘前价 12/17 04:11 美东 | | 三五249 月 ♥ 白选 | | ● 快捷交易 | | 最高价 18.280 | 开盘价 17.500 | 成交量 86.74万 | | 最低价 17.500 | 昨收价 18.290 | 成交额 2540.84万 | | 平均价 29.292 | 市盈率TM 亏损 | 总市值 7.22亿 (1) | | 振 幅 4.26% | 市盈率(静) 亏损 | 总股本 4013.36万 | | 换手率 3.85% | 市净率 13.652 | 流通值 4 ...

The after-hours market delivered a mixed but generally positive tone on Tuesday evening, with several small- and mid-cap names posting modest gains. One biotech, however, stole the spotlight with a dramatic surge following major clinical news.DBV Technologies S.A. (DBVT) dominated the after-hours session, soaring 61.29% to $29.00, up $11.02, after announcing a pivotal clinical milestone. The company reported that VITESSE, its Phase 3 study evaluating the VIASKIN Peanut patch in peanut-allergic children age ...

公司核心产品临床进展 - DBV Technologies宣布其针对4至7岁儿童的花生过敏贴片VIASKIN Peanut的III期VITESSE临床试验获得积极的顶线结果 [1] 公司未来计划与预期 - 公司提及多项前瞻性声明 包括对VIASKIN Peanut及EPIT疗法潜力的评论 [2] - 前瞻性声明涵盖临床和监管开发计划 以及预期临床试验的设计 [2] - 包括与监管机构互动的时机和结果 以及向美国FDA提交生物制品许可申请的计划和预期 [2] - 预期BLA可能有资格获得优先审评 并提及对BLA提交的预期支持 [2] - 提及2025年3月27日宣布的融资中发行的部分认股权证可能被投资者行权 以及预期募集资金用途 [2] - 包括对公司现金储备周期的预测 [2] - 提及若产品候选物获批 其改善食物过敏患者生活的潜力 [2]

DBV Technologies (NasdaqCM:DBVT) Update / Briefing December 16, 2025 05:00 PM ET Company ParticipantsPharis Mohideen - Chief Medical OfficerJonathan Neely - Head of Investor RelationsDaniel Tassé - CEOKevin Trapp - Chief Commercial OfficerConference Call ParticipantsAbby Gray - AnalystKristen Kluska - AnalystJon Wolleben - AnalystYatin Suneja - AnalystSam Slutsky - AnalystSushila Hernandez - AnalystOperatorWelcome to the DBV Technologies Update conference call. All participants will be in a listen-only mode ...

Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Sa ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting DBV Technologies S.A. ( DBVT ) in the spotlight. The company is based overseas and therefore gets relatively little coverage from Wall Street. The company is moving towards filing a key marketing application early ne ...